Physician profile
Sait Ashina
NPI 1194042895
$271,742.74
in general payments reported to CMS, 2019-2025
19 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $23K · 2021: $18K · 2022: $18K · 2023: $70K · 2024: $44K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $77K · Travel and Lodging: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Honoraria: $14K · Food and Beverage: $5,071 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $77,005.65 |
| Travel and Lodging | $36,814.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,275.00 |
| Honoraria | $14,400.00 |
| Food and Beverage | $5,071.49 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $66,365.95 | 2019-2024 | Emgality |
| Abbvie INC. | $44,596.11 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $37,224.08 | 2023-2025 | |
| Lilly USA, LLC | $32,398.34 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $28,873.24 | 2019-2025 | Ajovy |
| Allergan, INC. | $25,149.21 | 2019-2021 | |
| Lundbeck LLC | $10,719.72 | 2020-2025 | Vyepti |
| Axsome Therapeutics, INC. | $8,418.55 | 2025 | Symbravo |
| H. Lundbeck A S | $6,650.00 | 2024 | Vyepti |
| Supernus Pharmaceuticals, INC. | $4,490.92 | 2019 | |
| Amgen INC. | $2,763.41 | 2019-2022 | |
| Pfizer International LLC | $2,440.00 | 2025 | |
| Tonix Medicines, INC. | $651.53 | 2023-2025 | Zembrace Symtouch |
| Impel Pharmaceuticals INC. | $362.14 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $216.61 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $192.70 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $191.01 | 2021 | |
| Nalu Medical, INC. | $39.22 | 2024 | Nalu Neurostimulation System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sait Ashina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.